Carisma, Guillerma .

HRN: 02-87-18  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/08/2025
CO-AMOXICLAV 625MG (TAB)
04/08/2025
04/15/2025
PO
625mg
Tid
Soft Tissue Swelling Sec. To Punctured Wound
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: